|Awarded On||May 18, 2022|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||William Hudson|
|Cancer Sites||Brain and Other Nervous System, Breast, Lung and Bronchus|
|Summary of Goals and Objectives||
CD8+ T cells are an important arm of the adaptive immune system with the capability to kill cells presenting non-self or mutated-self antigen through MHC I. In conditions of antigen persistence, such as cancer, CD8+ T cells differentiate into an “exhausted” state characterized by lack of cytotoxic capacity, diminished proliferative potential, and expression of co-inhibitory signaling molecules that further suppress T cell function. Antibodies that inhibit these co-inhibitory signaling pathways, such as PD-1 blocking antibodies, have been approved for the treatment of multiple cancer types. However, most cancer patients do not respond to existing immunotherapies, highlighting the need for add...